• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结肠癌患者的肿瘤坏死、全身炎症、身体组成与生存之间的关系。

The relationship between tumour necrosis, systemic inflammation, body composition and survival in patients with colon cancer.

作者信息

Dolan Ross D, Pennel Kathryn, Thompson Joshua, McKenzie Molly, Alexander Peter, Richards Colin, Black Douglas, Abbass Tanvir, Maka Noori, McGovern Josh, Roseweir Antonia, McSorley Stephen T, Horgan Paul G, Roxburgh Campbell, McMillan Donald C, Edwards Joanne

机构信息

Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.

School of Cancer Sciences, University of Glasgow, Glasgow, UK.

出版信息

BJC Rep. 2025 Feb 5;3(1):7. doi: 10.1038/s44276-024-00119-w.

DOI:10.1038/s44276-024-00119-w
PMID:39910331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11799379/
Abstract

BACKGROUND

In cancer cachexia the relationship between the tumour, its environment and the systemic inflammatory response is not clear. This study aims to examine this relationship in greater detail.

METHODS

Host characteristics included the presence of a Systemic Inflammatory Response (SIR) as measured by Systemic Inflammatory Grade (SIG), sarcopenia (SMI) and myosteatosis (SMD) were measured. Categorical variables were analysed using χ test for linear-by-linear association, or χ test for 2 by 2 tables. Survival analysis was carried out using univariate and multivariate Cox regression.

RESULTS

A total of 473 patients were included. Of these, 70.4% were over 65 years of age, 54.8% were male and 49.8% had an ASA grade of 1 or 2. Pathological examination showed that the majority of patients had a T3 (53.7%) or a T4 (34.0%) cancer and 73.0% had evidence of necrosis. A SIG score of 0 or 1 was present in 57.7% of patients. Tumour necrosis was associated with age (p < 0.01), tumour location (p < 0.01), T-stage (p < 0.001), margin involvement (p < 0.05), SIG (p < 0.001), SMI (p < 0.01), SMD (p < 0.05) and 5-year survival (p < 0.001). On multivariate survival analysis in patients with T3 cancers age (HR: 1.45 95% CI 1.13-1.86 p < 0.01), ASA grade (HR: 1.50 95% CI 1.15-1.95 p < 0.01) and SIG (HR: 1.28 95% CI 1.11-1.48 p < 0.001) remained independently associated with survival.

CONCLUSION

These results suggest that tumour necrosis and the subsequent SIR could result in profound changes in body composition and survival. Further pre-clinical and clinical work is required to prove causation.

摘要

背景

在癌症恶病质中,肿瘤、其周围环境与全身炎症反应之间的关系尚不清楚。本研究旨在更详细地探讨这种关系。

方法

测量宿主特征,包括通过全身炎症分级(SIG)测量的全身炎症反应(SIR)的存在情况、肌肉减少症(SMI)和肌脂肪变性(SMD)。分类变量使用线性趋势χ检验或2×2列联表χ检验进行分析。生存分析采用单因素和多因素Cox回归。

结果

共纳入473例患者。其中,70.4%的患者年龄超过65岁,54.8%为男性,49.8%的患者美国麻醉医师协会(ASA)分级为1或2级。病理检查显示,大多数患者患有T3期(53.7%)或T4期(34.0%)癌症,73.0%有坏死证据。57.7%的患者SIG评分为0或1。肿瘤坏死与年龄(p<0.01)、肿瘤位置(p<0.01)、T分期(p<0.001)、切缘受累情况(p<0.05)、SIG(p<0.001)、SMI(p<0.01)、SMD(p<0.05)和5年生存率(p<0.001)相关。在T3期癌症患者的多因素生存分析中,年龄(风险比:1.45,95%置信区间1.13 - 1.86,p<0.01)、ASA分级(风险比:1.50,95%置信区间1.15 - 1.95,p<0.01)和SIG(风险比:1.28,95%置信区间1.11 - 1.48,p<0.001)仍然与生存独立相关。

结论

这些结果表明,肿瘤坏死及随后的全身炎症反应可能导致身体组成和生存的深刻变化。需要进一步的临床前和临床研究来证实因果关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830e/11799379/1b09cfffb449/44276_2024_119_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830e/11799379/ca4ac21fc568/44276_2024_119_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830e/11799379/1b09cfffb449/44276_2024_119_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830e/11799379/ca4ac21fc568/44276_2024_119_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830e/11799379/1b09cfffb449/44276_2024_119_Fig2_HTML.jpg

相似文献

1
The relationship between tumour necrosis, systemic inflammation, body composition and survival in patients with colon cancer.结肠癌患者的肿瘤坏死、全身炎症、身体组成与生存之间的关系。
BJC Rep. 2025 Feb 5;3(1):7. doi: 10.1038/s44276-024-00119-w.
2
The relationship between the mode of presentation, CT-derived body composition, systemic inflammatory grade and survival in colon cancer.结直肠癌患者的临床表现、CT 体成分、全身炎症程度与生存的关系。
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2863-2874. doi: 10.1002/jcsm.13097. Epub 2022 Oct 11.
3
The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer.结直肠癌患者接受手术治疗时,体成分、全身炎症反应与生存的关系:基于 CT 扫描的研究
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):111-122. doi: 10.1002/jcsm.12357. Epub 2018 Nov 20.
4
CT-derived body composition and differential association with age, TNM stage and systemic inflammation in patients with colon cancer.CT 衍生的身体成分与结肠癌患者年龄、TNM 分期和全身炎症的差异关联。
Sci Rep. 2024 Jul 8;14(1):15673. doi: 10.1038/s41598-024-65871-y.
5
The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer.结直肠癌患者的肿瘤分期、全身炎症、身体成分与生存的关系。
Clin Nutr. 2018 Aug;37(4):1279-1285. doi: 10.1016/j.clnu.2017.05.017. Epub 2017 May 19.
6
The relationship between F-FDG-PETCT-derived tumour metabolic activity, nutritional risk, body composition, systemic inflammation and survival in patients with lung cancer.肺癌患者的 F-FDG-PET/CT 肿瘤代谢活性、营养风险、身体成分、全身炎症与生存的关系。
Sci Rep. 2020 Nov 30;10(1):20819. doi: 10.1038/s41598-020-77269-7.
7
The relationship between computed tomography-derived body composition, systemic inflammation, and survival in patients with abdominal aortic aneurysm.基于 CT 的体成分、全身炎症与腹主动脉瘤患者生存的关系。
J Vasc Surg. 2023 Oct;78(4):937-944.e4. doi: 10.1016/j.jvs.2023.06.012. Epub 2023 Jun 28.
8
The relationship between the modified frailty index score (mFI-5), malnutrition, body composition, systemic inflammation and short-term clinical outcomes in patients undergoing surgery for colorectal cancer.改良衰弱指数评分(mFI-5)、营养不良、身体成分、全身炎症与结直肠癌手术患者短期临床结局的关系。
BMC Geriatr. 2023 Jan 6;23(1):9. doi: 10.1186/s12877-022-03703-2.
9
The combination of body composition conditions and systemic inflammatory markers has prognostic value for patients with gastric cancer treated with adjuvant chemoradiotherapy.体成分状况与全身炎症标志物联合对接受辅助放化疗的胃癌患者具有预后价值。
Nutrition. 2022 Jan;93:111464. doi: 10.1016/j.nut.2021.111464. Epub 2021 Sep 17.
10
The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer.右侧肿瘤位置、肿瘤微环境、全身炎症、辅助治疗与结直肠癌患者手术预后的关系。
Br J Cancer. 2018 Mar 6;118(5):705-712. doi: 10.1038/bjc.2017.441. Epub 2018 Jan 16.

本文引用的文献

1
Tocilizumab for Advanced Non-Small-Cell Lung Cancer With Concomitant Cachexia: An Observational Study.托珠单抗用于伴发恶病质的晚期非小细胞肺癌:一项观察性研究。
J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2815-2825. doi: 10.1002/jcsm.13638. Epub 2024 Nov 11.
2
Ponsegromab for the Treatment of Cancer Cachexia.泊塞格单抗用于治疗癌症恶病质。
N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14.
3
Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series.
癌症恶病质临床试验中的生物标志物终点:恶病质终点系列的系统评价 5。
J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):853-867. doi: 10.1002/jcsm.13491. Epub 2024 May 23.
4
Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series.癌症恶病质临床试验中的体重和组成终点:恶病质终点系列的系统评价 4。
J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):816-852. doi: 10.1002/jcsm.13478. Epub 2024 May 13.
5
Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series.癌症恶病质临床试验中的生活质量终点:恶病质终点系列的系统评价 3。
J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):794-815. doi: 10.1002/jcsm.13453. Epub 2024 Mar 29.
6
Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series.癌症恶病质临床试验中的食欲和饮食摄入终点:恶病质终点系列的系统评价 2。
J Cachexia Sarcopenia Muscle. 2024 Apr;15(2):513-535. doi: 10.1002/jcsm.13434. Epub 2024 Feb 11.
7
Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series.癌症恶病质临床试验中的身体功能终点:恶病质终点系列的系统综述 1。
J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1932-1948. doi: 10.1002/jcsm.13321. Epub 2023 Sep 6.
8
Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer.炎症生物标志物在结肠癌患者中的评估及预后价值
JAMA Oncol. 2023 Aug 1;9(8):1152-1153. doi: 10.1001/jamaoncol.2023.1529.
9
Immunological and prognostic significance of tumour necrosis in colorectal cancer.结直肠癌肿瘤坏死的免疫和预后意义。
Br J Cancer. 2023 Jun;128(12):2218-2226. doi: 10.1038/s41416-023-02258-2. Epub 2023 Apr 8.
10
Lactate dehydrogenase: relationship with the diagnostic GLIM criterion for cachexia in patients with advanced cancer.乳酸脱氢酶:与晚期癌症恶病质患者 GLIM 诊断标准的关系。
Br J Cancer. 2023 Mar;128(5):760-765. doi: 10.1038/s41416-022-02099-5. Epub 2022 Dec 14.